Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × INDUSTRY × NVX-CoV2373 adjuvated lipid nanoparticle × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

fludarabine 8 Cyclophosphamide 8 pembrolizumab 4 Oncolytic Virotherapy 3 Cholestanetriol 26-Monooxygenase 3 alpha-Synuclein 2 Trastuzumab 2 Nivolumab 2 Influenza Vaccines 2 Blood Specimen Collection 2 Ascorbic Acid 2 spartalizumab 1 ruxolitinib 1 reolysin 1 pexidartinib 1 methyl prednisolonate 1 irinotecan sucrosofate 1 fiu protein, E coli 1 camrelizumab 1 avelumab 1 atezolizumab 1 apatinib 1 VTX-2337 1 Temozolomide 1 TAK-981 1 Sorafenib 1 Radiation 1 RXDX-106 1 Positron-Emission Tomography 1 Pluvicto 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03305341 2025-06-11

COVSP-BCG

Medicine Invention Design, Inc

Phase EARLY_PHASE1 Active not recruiting

COVID-19

Data powered by HemOnc (CC BY 4.0) Colophon ⚡